
PharmaEssentia Selects Pint-Pharma as Commercial Partner for BESREMi® (ropeginterferon alfa-2b-njft) in Latin America
TAIPEI–(BUSINESS WIRE)–PharmaEssentia Corporation (TPEx:6446), a leading fully integrated biopharmaceutical company in Taiwan, today announced that it has entered into an exclusive license agreement with Pint-Pharma […]












